查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827771

2025年照護現場分子診斷全球市場報告

Point-Of-Care Molecular Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，照護現場分子診斷市場規模迅速擴張，從2024年的35.5億美元成長至2025年的39.8億美元，複合年成長率為12.0%。預測期內的成長可歸因於快速疾病診斷需求的不斷成長、感染疾病的不斷增加、遠端醫療和遠距檢測的擴展、照護現場的監管支持以及對個人化和精準醫療的需求。

預計未來幾年照護現場分子診斷市場將快速成長，到2029年將達到69.2億美元，複合年成長率為14.8%。預測期內的成長可歸因於診斷設備的小型化、癌症和遺傳疾病即時檢測的擴展、面向各種應用的客製化分子診斷、人工智慧和機器學習在數據分析中的整合以及新興感染疾病的監測。預測期內的主要趨勢包括實驗室晶片和微流體技術、數位健康和​​基於智慧型手機的診斷、照護現場COVID-19和疫情應對措施、人工智慧主導的預測性診斷以及基於Crisp®的分子檢測。

即時診斷 (POC) 分子診斷旨在檢測臨床檢體（例如糞便、唾液、尿液、血液和組織）中的特定核酸。這些診斷方法依賴於識別微生物遺傳物質的目標片段，特別是 DNA 或 RNA。 POC 分子診斷廣泛應用於醫療保健領域，已獲得緊急使用授權 (EUA)，可用於診斷多種疾病。這些診斷方法可用於檢測人體樣本中的疾病抗原和抗體，包括單核球增多症、流感和 A 型鏈球菌(GAS) 的抗原和抗體。

照護現場分子診斷領域的關鍵產品和服務包括檢測試劑套件、儀器和分析儀以及軟體和服務。檢測試劑套件是用於進行分析的儀器，特別適用於疾病通路研究。它們常用於快速且準確地診斷和監測各種疾病。即時分子診斷採用逆轉錄聚合酵素鏈鎖反應(RT-PCR)、原位雜合反應和定序等技術來診斷呼吸系統疾病、院內感染 (HAI)、癌症/腫瘤、肝炎和血液疾病等疾病。照護現場分子診斷廣泛應用於醫療機構，例如分散式實驗室、醫院、居家照護和輔助生活機構。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要醫療設備重新認證，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供照護現場診斷市場統計數據，包括全球市場規模、區域佔有率、競爭對手的照護現場診斷市場佔有率、照護現場照護現場診斷的詳細細分市場、市場趨勢和商機，以及您在照護現場診斷行業取得成功所需的數據。照護現場分子診斷市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切觀點。

未來五年14.8%的預測成長率比我們先前對該市場的預測略有下降0.2個百分點。這一下降主要源自於美國與其他國家之間關稅的影響。這種影響可能會直接影響美國，透過提高進口恆溫擴增酶和微晶片陣列（主要來自英國和以色列）的關稅，從而提高攜帶式傳染病檢查的成本。由於互惠關稅以及不斷升級的貿易摩擦和貿易限制對全球經濟和貿易的負面影響，這種影響也將更加廣泛。

感染疾病和呼吸道疾病盛行率的大幅上升預計將成為照護現場分子診斷市場成長的主要驅動力。引起呼吸道感染疾病的微生物，無論是病毒或細菌，都會透過咳嗽、打噴嚏和直接接觸等多種方式傳播。這些疾病的嚴重性需要各種治療方法，包括吸入藥物、口服藥物、靜脈注射療法和照護現場診斷，以有效地患者照護。例如，根據英國國家統計局的數據，35 至 69 歲人群和 12 至 24 歲的學齡兒童的感染率有所上升，這凸顯了對有效的照護現場診斷以應對感染疾病和呼吸道疾病的迫切需求。

人們對心臟衰竭治療的認知不斷提高，推動了照護現場(POC) 分子診斷市場的成長。心臟衰竭是一種影響心臟有效泵血能力的疾病，POC 分子診斷可以透過提供快速且準確的診斷，實現早期療育並改善患者預後，從而帶來顯著優勢。根據美國心臟協會的報告，心臟衰竭診斷數量呈上升趨勢，預計到 2030 年將增加 46%，達到 800 多萬心臟衰竭患者。在印度，農村和都市區的冠狀動脈疾病發生率都在迅速增加。人們對心臟衰竭治療的認知不斷提高，凸顯了 POC 分子診斷在這一醫療領域可以發揮的重要作用。

推動照護現場的關鍵趨勢是技術創新。主要市場參與企業正致力於提供先進的解決方案，以鞏固其市場地位。各公司正將酵素結合免疫吸附檢測法(ELISA)、聚合酵素鏈鎖反應(PCR)、質譜 (MS)、原位雜合反應、頻譜核型分析成像和 DNA 微陣列等新一代技術融入其即時分子診斷 (POC) 設備，以縮短分析時間並降低成本。例如，Sensible Diagnostics 推出了一款可在 10 分鐘內提供結果的即時分子診斷系統，展現了其在快速提供結果方面的技術進步。

照護現場（POC）分子診斷市場的主要參與者正在積極建立策略夥伴關係關係，以推出基於 CRISPR 的即時診斷檢測。例如，CrisprBits 已與 MolBio Diagnostics 合作，利用其生物技術專業知識以及翻譯、生產和分銷能力，開發用於檢測病原體和基因標記的即時診斷檢測。

2024年7月，總部位於瑞士、專注於藥物、治療方法和診斷開發的全球醫療保健公司羅氏控股有限公司（Roche Holding AG）收購了Lumiradex Ltd.，收購金額未披露。此次收購旨在增強羅氏控股有限公司的診斷產品組合，改善分散式醫療保健解決方案的可近性，並提升檢測能力，尤其是在醫療資源匱乏的地區。 LumiraDx Ltd.是一家總部位於英國的診斷公司，專注於開發創新的照護現場（POC）檢測解決方案。

在照護現場分子診斷市場運作的主要企業包括雅培實驗室、羅氏公司、生物梅里埃公司、丹納赫公司、Quidel 公司、生物梅里埃公司、Bio-Rad Laboratories Inc.、Sysmex 公司、Illumina 公司、Myriad Genetics Inc.、西門子醫療有限公司、Almacator 公司、Illumina 公司、Myriad Genetics Inc.、西門子醫療有限公司、Almacator 集團、Biogenpication Inc. Inc.、Genomic Health Inc、Grail、Hologic、HTG Molecular Diagnostics、Inivata、Invivoscribe、MolecularMD、Natera、NeoGenomics Laboratories、Personal Genome Diagnostics、Prometheus Laboratories、Ventana Medical Systems、Vermillion、Guardal Genome Diagnostics、Prometheus Laboratories、Ventana Medical Systems、Vermillion、Guardant Health、Exact Sciences 和 Biocartis Group。 NV、ArcherDx、Bio-Techne、AccuBiotech Co.Ltd.、Becton, Dickinson and Company、Chembio Diagnostics Inc.、Credo Diagnostics Biomedical Pvt. Ltd.、EKF Diagnostics、GenePOC Inc.

2024年，北美是照護現場分子診斷市場最大的地區。預計亞太地區將成為預測期內成長最快的地區。照護現場分子診斷市場分析報告涵蓋亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。

照護現場分子診斷市場分析報告涵蓋的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國和美國。

照護現場(POC) 分子診斷市場包括 AAT、抗原和抗體檢測的收益。市場價值包括服務供應商銷售或包含在其服務產品中的相關商品的價值。僅包括企業之間交易或銷售給最終消費者的商品和服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球照護現場分子診斷：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球照護現場分子診斷市場：成長率分析
  • 全球照護現場分子診斷市場表現：規模與成長，2019-2024
  • 全球照護現場分子診斷市場預測：規模與成長，2024-2029 年，2034 年預測
  • 全球照護現場分子診斷：總潛在市場（TAM）

第6章 市場細分

  • 全球照護現場診斷分子診斷市場（依產品及服務、績效及預測）2019-2024 年、2024-2029 年、2034 年
  • 檢測方法和套件
  • 儀器和分析設備
  • 軟體和服務
  • 全球照護現場分子診斷市場：依技術、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 逆轉錄聚合酵素鏈鎖反應（RT-PCR）
  • 原位雜合技術
  • 定序
  • 全球照護現場分子診斷市場：依應用、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 呼吸系統疾病
  • 院內感染（HAI）
  • 癌症/腫瘤學
  • 肝炎
  • 血液學
  • 全球照護現場分子診斷市場：按最終用戶、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 分散式實驗室
  • 醫院
  • 居家護理
  • 輔助醫療設施
  • 全球照護現場分子診斷市場：依檢測及套件類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 核酸增幅檢查（NAAT）
  • 快速診斷測試
  • 分子檢測試劑套件
  • 試劑和耗材
  • 全球照護現場分子診斷市場：按儀器和分析設備（按類型）細分，實際和預測，2019-2024 年、2024-2029 年、2034 年
  • PCR儀
  • 微流體設備
  • 序列器
  • 照護現場分析儀
  • 全球照護現場分子診斷市場：依軟體及服務細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 資料管理軟體
  • 雲端基礎的解決方案
  • 技術支援和維護服務
  • 諮詢和培訓服務

第7章 區域和國家分析

  • 全球照護現場分子診斷市場：區域表現及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 全球照護現場分子診斷市場：依國家/地區、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 照護現場分子診斷市場：競爭格局
  • 照護現場分子診斷市場：公司簡介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • BioMerieux SA Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Quidel Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • BioMerieux SA
  • Bio-Rad Laboratories Inc.
  • Sysmex Corporation
  • Illumina Inc.
  • Myriad Genetics Inc.
  • Siemens Healthcare GmbH
  • Almac Group
  • Biogenex Laboratories Inc.
  • Cepheid Inc.
  • Epic Sciences Inc.
  • Foundation Medicine Inc.
  • Genomic Health Inc.
  • Grail Inc.
  • Hologic Inc.
  • HTG Molecular Diagnostics Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029 年照護現場診斷分子診斷市場：提供新機會的國家
  • 2029 年照護現場診斷分子診斷市場：細分市場將帶來新機會
  • 2029 年照護現場診斷分子診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r21949u

Point-of-care (POC) molecular diagnostics are tests designed to detect specific nucleic acids in clinical specimens, including feces, saliva, urine, blood, and tissue. These diagnostics rely on identifying targeted portions of microbial genetic material, specifically DNA or RNA. Widely utilized in the healthcare sector, POC molecular diagnostics are granted emergency usage authorization to diagnose various diseases. These diagnostics are instrumental in detecting disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS).

The primary products and services in point-of-care molecular diagnostics include assays and kits, instruments and analyzers, and software and services. Assays and kits are equipment used to carry out analyses, especially in studying disease pathways. They are commonly employed for rapid and accurate diagnosis and monitoring of various diseases. Technologies such as reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, and sequencing are utilized in POC molecular diagnostics for diagnosing diseases like respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis, and hematology. Point-of-care molecular diagnostics are employed in decentralized labs, hospitals, home care, and assisted living healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The point-of-care molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The point-of-care molecular diagnostics market size has grown rapidly in recent years. It will grow from $3.55 billion in 2024 to $3.98 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increasing demand for rapid disease diagnosis, growth in infectious disease outbreaks, expansion of telemedicine and remote testing, regulatory support for point-of-care diagnostics, need for personalized and precision medicine.

The point-of-care molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to miniaturization of diagnostic devices, expansion of poc testing for cancer and genetic diseases, customized molecular diagnostics for diverse applications, integration of ai and machine learning for data analysis, emerging infectious disease surveillance. Major trends in the forecast period include lab-on-a-chip and microfluidic technologies, digital health and smartphone-based diagnostics, point-of-care covid-19 and pandemic preparedness, ai-driven predictive diagnostics, crispr-based molecular testing.

The forecast of 14.8% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through increased tariffs on isothermal amplification enzymes and microchip arrays, mainly imported from the UK and Israel, raising costs for portable infectious disease testing.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The significant rise in the prevalence of infectious and respiratory diseases is anticipated to be a major driver for the growth of the point-of-care molecular diagnostics market. Microorganisms causing respiratory infections, whether viral or bacterial, can spread through various means, including coughing, sneezing, or direct contact. The severity of these diseases necessitates a range of treatments, including inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostics for effective patient care. For example, in England, according to the Office for National Statistics, the infection rate increased among individuals aged 35 to 69 and those in school years 12 to 24, highlighting the urgency for effective point-of-care molecular diagnostics to address infectious and respiratory diseases.

The increasing awareness regarding heart failure treatment is poised to propel the growth of the point-of-care (POC) molecular diagnostics market. Heart failure, a condition impacting the heart's ability to pump blood effectively, can benefit significantly from POC molecular diagnostics, offering swift and accurate diagnoses for early interventions and improved patient outcomes. The American Heart Association reports a rising number of heart failure diagnoses, projected to increase by 46% by 2030, exceeding 8 million people with heart failure. In India, coronary incidences have surged in both rural and urban populations. This growing awareness about heart failure treatment underscores the potential for POC molecular diagnostics to play a crucial role in this medical domain.

A key trend gaining traction in the point-of-care molecular diagnostics market is technological innovation. Major market players are dedicated to providing advanced solutions to strengthen their market positions. Companies are incorporating next-generation technologies such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, etc., on POC devices, accelerating analysis times and reducing costs. For instance, Sensible Diagnostics introduced a 10-minute point-of-care PCR system, showcasing technological advancements to provide rapid results.

Strategic partnerships are being embraced by major players in the point-of-care molecular diagnostics market to launch POC CRISPR-based tests. For instance, CrisprBits collaborated with MolBio Diagnostics to leverage biotechnology expertise and translation, manufacturing, and distribution capabilities for developing POC tests detecting pathogens and genetic markers.

In July 2024, Roche Holding AG, a Switzerland-based global healthcare company focused on developing medicines, treatments, and diagnostics, acquired LumiraDx Ltd. for an undisclosed amount. This acquisition is intended to enhance Roche Holding AG's diagnostics portfolio, improve access to decentralized healthcare solutions, and expand testing capabilities, especially in underserved regions. LumiraDx Ltd. is a UK-based diagnostic company that specializes in creating innovative point-of-care (POC) testing solutions.

Major companies operating in the point-of-care molecular diagnostics market include Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMerieux SA, Danaher Corporation, Quidel Corporation, BioMerieux SA, Bio-Rad Laboratories Inc., Sysmex Corporation, Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Biogenex Laboratories Inc., Cepheid Inc., Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Prometheus Laboratories Inc., Ventana Medical Systems Inc., Vermillion Inc., Guardant Health Inc., Exact Sciences Corporation, Biocartis Group NV, ArcherDx Inc., Bio-Techne Corporation, AccuBiotech Co. Ltd., Becton, Dickinson and Company, Chembio Diagnostics Inc., Credo Diagnostics Biomedical Pvt. Ltd., EKF Diagnostics, GenePOC Inc.

North America was the largest region in the point-of-care molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Point-Of-Care Molecular Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on point-of-care molecular diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for point-of-care molecular diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care molecular diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product And Service: Assays And Kits; Instruments And Analyzers; Software And Services
  • 2) By Technology: Reverse Transcription - Polymerase Chain Reaction (RT-PCR); In Situ Hybridization; Sequencing
  • 3) By Application: Respiratory Diseases; Hospital Acquired Infections (HAIs); Cancer/Oncology; Hepatitis; Hematology
  • 4) By End-User: Decentralized Labs; Hospitals; Home Care; Assisted Living Healthcare Facilities
  • Subsegments:
  • 1) By Assays And Kits: Nucleic Acid Amplification Tests (NAATs); Rapid Diagnostic Tests; Molecular Detection Kits; Reagents And Consumables
  • 2) By Instruments And Analyzers: PCR Machines; Microfluidic Devices; Sequencers; Point-of-Care Analyzers
  • 3) By Software And Services: Data Management Software; Cloud-Based Solutions; Technical Support And Maintenance Services; Consultation And Training Services
  • Companies Mentioned: Abbott Laboratories; F Hoffmann-La Roche Ltd.; BioMerieux SA; Danaher Corporation; Quidel Corporation; BioMerieux SA; Bio-Rad Laboratories Inc.; Sysmex Corporation; Illumina Inc.; Myriad Genetics Inc.; Siemens Healthcare GmbH; Almac Group; Biogenex Laboratories Inc.; Cepheid Inc.; Epic Sciences Inc.; Foundation Medicine Inc.; Genomic Health Inc.; Grail Inc.; Hologic Inc.; HTG Molecular Diagnostics Inc.; Inivata Ltd.; Invivoscribe Inc.; MolecularMD Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Personal Genome Diagnostics Inc.; Prometheus Laboratories Inc.; Ventana Medical Systems Inc.; Vermillion Inc.; Guardant Health Inc.; Exact Sciences Corporation; Biocartis Group NV; ArcherDx Inc.; Bio-Techne Corporation; AccuBiotech Co. Ltd.; Becton, Dickinson and Company; Chembio Diagnostics Inc.; Credo Diagnostics Biomedical Pvt. Ltd.; EKF Diagnostics; GenePOC Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Point-Of-Care Molecular Diagnostics Market Characteristics

3. Point-Of-Care Molecular Diagnostics Market Trends And Strategies

4. Point-Of-Care Molecular Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Point-Of-Care Molecular Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Point-Of-Care Molecular Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Point-Of-Care Molecular Diagnostics Market Growth Rate Analysis
  • 5.4. Global Point-Of-Care Molecular Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Point-Of-Care Molecular Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Point-Of-Care Molecular Diagnostics Total Addressable Market (TAM)

6. Point-Of-Care Molecular Diagnostics Market Segmentation

  • 6.1. Global Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Assays And Kits
  • Instruments And Analyzers
  • Software And Services
  • 6.2. Global Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reverse Transcription - Polymerase Chain Reaction (RT-PCR)
  • In Situ Hybridization
  • Sequencing
  • 6.3. Global Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Respiratory Diseases
  • Hospital Acquired Infections (HAIs)
  • Cancer/Oncology
  • Hepatitis
  • Hematology
  • 6.4. Global Point-Of-Care Molecular Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Decentralized Labs
  • Hospitals
  • Home Care
  • Assisted Living Healthcare Facilities
  • 6.5. Global Point-Of-Care Molecular Diagnostics Market, Sub-Segmentation Of Assays And Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nucleic Acid Amplification Tests (NAATs)
  • Rapid Diagnostic Tests
  • Molecular Detection Kits
  • Reagents And Consumables
  • 6.6. Global Point-Of-Care Molecular Diagnostics Market, Sub-Segmentation Of Instruments And Analyzers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR Machines
  • Microfluidic Devices
  • Sequencers
  • Point-of-Care Analyzers
  • 6.7. Global Point-Of-Care Molecular Diagnostics Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Management Software
  • Cloud-Based Solutions
  • Technical Support And Maintenance Services
  • Consultation And Training Services

7. Point-Of-Care Molecular Diagnostics Market Regional And Country Analysis

  • 7.1. Global Point-Of-Care Molecular Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Point-Of-Care Molecular Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Point-Of-Care Molecular Diagnostics Market

  • 8.1. Asia-Pacific Point-Of-Care Molecular Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Point-Of-Care Molecular Diagnostics Market

  • 9.1. China Point-Of-Care Molecular Diagnostics Market Overview
  • 9.2. China Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Point-Of-Care Molecular Diagnostics Market

  • 10.1. India Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Point-Of-Care Molecular Diagnostics Market

  • 11.1. Japan Point-Of-Care Molecular Diagnostics Market Overview
  • 11.2. Japan Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Point-Of-Care Molecular Diagnostics Market

  • 12.1. Australia Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Point-Of-Care Molecular Diagnostics Market

  • 13.1. Indonesia Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Point-Of-Care Molecular Diagnostics Market

  • 14.1. South Korea Point-Of-Care Molecular Diagnostics Market Overview
  • 14.2. South Korea Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Point-Of-Care Molecular Diagnostics Market

  • 15.1. Western Europe Point-Of-Care Molecular Diagnostics Market Overview
  • 15.2. Western Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Point-Of-Care Molecular Diagnostics Market

  • 16.1. UK Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Point-Of-Care Molecular Diagnostics Market

  • 17.1. Germany Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Point-Of-Care Molecular Diagnostics Market

  • 18.1. France Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Point-Of-Care Molecular Diagnostics Market

  • 19.1. Italy Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Point-Of-Care Molecular Diagnostics Market

  • 20.1. Spain Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Point-Of-Care Molecular Diagnostics Market

  • 21.1. Eastern Europe Point-Of-Care Molecular Diagnostics Market Overview
  • 21.2. Eastern Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Point-Of-Care Molecular Diagnostics Market

  • 22.1. Russia Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Point-Of-Care Molecular Diagnostics Market

  • 23.1. North America Point-Of-Care Molecular Diagnostics Market Overview
  • 23.2. North America Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Point-Of-Care Molecular Diagnostics Market

  • 24.1. USA Point-Of-Care Molecular Diagnostics Market Overview
  • 24.2. USA Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Point-Of-Care Molecular Diagnostics Market

  • 25.1. Canada Point-Of-Care Molecular Diagnostics Market Overview
  • 25.2. Canada Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Point-Of-Care Molecular Diagnostics Market

  • 26.1. South America Point-Of-Care Molecular Diagnostics Market Overview
  • 26.2. South America Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Point-Of-Care Molecular Diagnostics Market

  • 27.1. Brazil Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Point-Of-Care Molecular Diagnostics Market

  • 28.1. Middle East Point-Of-Care Molecular Diagnostics Market Overview
  • 28.2. Middle East Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Point-Of-Care Molecular Diagnostics Market

  • 29.1. Africa Point-Of-Care Molecular Diagnostics Market Overview
  • 29.2. Africa Point-Of-Care Molecular Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Point-Of-Care Molecular Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Point-Of-Care Molecular Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Point-Of-Care Molecular Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Point-Of-Care Molecular Diagnostics Market Competitive Landscape
  • 30.2. Point-Of-Care Molecular Diagnostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. BioMerieux SA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Quidel Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Point-Of-Care Molecular Diagnostics Market Other Major And Innovative Companies

  • 31.1. BioMerieux SA
  • 31.2. Bio-Rad Laboratories Inc.
  • 31.3. Sysmex Corporation
  • 31.4. Illumina Inc.
  • 31.5. Myriad Genetics Inc.
  • 31.6. Siemens Healthcare GmbH
  • 31.7. Almac Group
  • 31.8. Biogenex Laboratories Inc.
  • 31.9. Cepheid Inc.
  • 31.10. Epic Sciences Inc.
  • 31.11. Foundation Medicine Inc.
  • 31.12. Genomic Health Inc.
  • 31.13. Grail Inc.
  • 31.14. Hologic Inc.
  • 31.15. HTG Molecular Diagnostics Inc.

32. Global Point-Of-Care Molecular Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Point-Of-Care Molecular Diagnostics Market

34. Recent Developments In The Point-Of-Care Molecular Diagnostics Market

35. Point-Of-Care Molecular Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Point-Of-Care Molecular Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Point-Of-Care Molecular Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Point-Of-Care Molecular Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer